Physician
Oncology
Dr. Rogerio C. Lilenbaum, MD
|
|
Give Review
Rogerio C. Lilenbaum, MD is an expert in the field of Oncology. He over the years received 8 awards: "Top Doctors: New York Metro Area", "America's Top Doctors", "America's Top Doctors for Cancer", "Top Doctors:South Florida", "Gulfstream FL-Broward", "CMS Meaningful Use Stage 1 Certification", "Fellow (FACP)" and "Super Doctor". Rogerio Lilenbaum is also published. He has 78 publications published. The lastest publication: "Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.' Doctor Rogerio C. Lilenbaum, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
- Generalizability of trial results to elderly Medicare patients with advanced solid Tumors (Alliance 70802).
- A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor risk stage III non-small cell lung Cancer: Results of CALGB 30605 (A...
- American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes.
- Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non-Small-Cell Lung Cancer and Eastern Cooperative On...
- Stereotactic body radiotherapy in patients with stage I non-small-cell lung Cancer aged 75 years and older: retrospective results from a multicenter consortium.
- Small cell lung Cancer: past, present, and future.
- Accrual to National Cancer Institute-sponsored non-small-cell lung Cancer trials: insights and contributions from the CCOP program.
- New treatment strategies in patients with advanced non-small-cell lung Cancer and performance status 2.
- New horizons in chemotherapy: platforms for combinations in first-line advanced non-small cell lung Cancer.
- Summary statement novel agents in the treatment of lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
- Prevalence of poor performance status in lung Cancer patients: implications for research.
- Chemotherapy in patients > or = 80 with advanced non-small cell lung Cancer: combined results from SWOG 0027 and LUN 6.
- Should health-related quality of life be measured in Cancer symptom management clinical trials? Lessons learned using the functional assessment of Cancer therapy.
- Topotecan therapy in patients with relapsed small-cell lung Cancer and poor performance status.
- The evolving role of cetuximab in non-small cell lung Cancer.
- Summary statement: novel agents in the treatment of lung Cancer: advances in epidermal growth factor receptor-targeted agents.
- Single-agent versus combination chemotherapy in advanced non-small-cell lung Cancer: the Cancer and leukemia group B (study 9730).
- Treatment of patients with advanced lung Cancer and poor performance status.
- Treatment of advanced non-small-cell lung Cancer in special populations.
- Current trends in the treatment of advanced non-small cell lung Cancer (Review).
- Safe pulmonary resection after chemotherapy and high-dose thoracic radiation.
- Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung Cancer.
- Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung Cancer.
- Gemcitabine and vinorelbine in advanced nonsmall cell Lung carcinoma: a phase II study.
- The efficacy and cost effectiveness of new antiemetic guidelines.
- Options in advanced non-small cell lung Cancer: a review and report on a phase II study of vinorelbine plus gemcitabine.
- Chemotherapeutic management of stage IV non-small cell lung Cancer.
- Chemotherapy for elderly patients with advanced non-small-cell lung Cancer.
- Management of advanced non-small-cell lung Cancer in elderly populations.
- Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung Cancer.
- Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung Cancer trial participants.
- Chemotherapy for advanced non-small-cell lung Cancer.
- Primary hepatic Neuroendocrine carcinoma: an underdiagnosed entity.
- New developments in chemotherapy for advanced non-small cell lung Cancer.
- Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung Cancer.
- Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung Cancer.
- Phase II trial of cetuximab in patients with previously treated non-small-cell lung Cancer.
- Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung Cancer.
- A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung Cancer.
- Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
- Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung Cancer.
- Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung Cancer and a performance status of 2.
- Treatment of non-small cell lung Cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).
- Patients with non-small cell lung Cancer and poor performance status: a significant population with limited data.
- Role of chemotherapy in patients with poor performance status and advanced non-small cell lung Cancer.
- Combined modality therapy for limited-disease small cell lung Cancer.
- Management of advanced non-small-cell lung Cancer in patients with a performance status of 2.
- Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung Cancer.
- Differences in clinical trial patient attributes and outcomes according to enrollment setting.
- Phase II trial of combined modality therapy with myeloid growth factor support in patients with locally advanced non-small cell lung Cancer.
- Single-agent versus combination chemotherapy in patients with advanced non-small cell lung Cancer and a performance status of 2: prognostic factors and treatment selec...
- Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung Cancer and a performance status of 2: ...
- Molecular analysis-based treatment strategies for the management of non-small cell lung Cancer.
- Insulin growth factor pathway.
- Single-agent versus combination chemotherapy in advanced non-small cell lung Cancer: a meta-analysis and the Cancer and Leukemia Group B randomized trial.
- Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung Cancer.
- Vinorelbine and gemcitabine combinations in advanced non small-cell lung Cancer.
- Extranodal lymphoplasmacytoid Lymphoma (immunocytoma) presenting as small intestinal obstruction.
- Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell Lung carcinoma.
- [Mapping of inferior wall myocardial infarcts--a new method].
- Systemic treatment of Kaposi's sarcoma: current status and future directions.
- Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a Cancer and leukemia group B study.
- A phase I trial of paclitaxel and etoposide for metastatic or recurrent malignancies.
- Phase I study of paclitaxel and topotecan in patients with advanced tumors: a Cancer and leukemia group B study.
- Interleukin 2-induced focal fatty infiltrate of the Liver that mimics metastases.
- Copper deficiency-induced Anemia and neutropenia secondary to intestinal malabsorption.
- Multimodality therapy for non-small-cell lung Cancer.
- Stage IIIA category of non-small-cell lung Cancer: a new proposal.
- Novel chemotherapeutic agents in the treatment of non-small-cell lung Cancer.
- Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity.
- Issues at the cutting edge in stage III non-small-cell lung Cancer.
- Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
- Recent advances in chemotherapy for lung Cancer.
- Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-Analysis of response, toxicity, and survival.
- Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies.
- Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced Cancer: a Cancer and LeukemiaGroup B study.
Schools
Universidade Federal Do Rio De Janeiro Centro De Ciencias Da Saude Faculdade De Medicina
University Hospital
University Calif San Diego
Washington University School Med
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Top Doctors: New York Metro Area
- America's Top Doctors
- America's Top Doctors for Cancer
- Top Doctors:South Florida
- Gulfstream FL-Broward
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACP)
- Super Doctor
Education
-
Washington University - Barnes-Jewish Hospital -
Faculdade de Medicina da Universidade Federal do Rio de Janeiro
Drug Facts
| NPI NUMBER | 1669460366 | |
| NPPES Provider LastName | LILENBAUM | |
| NPPES Provider FirstName | ROGERIO | |
| NPPES Provider ZIPCode | 065103220 | |
| NPPES Provider State | CT | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 13.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1669460366 |
| Last Name Of The Provider | LILENBAUM |
| First Name Of The Provider | ROGERIO |
| View All |
Similar Doctors
|
Dr. Lawrence A. Snetman, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Arnold S. Blaustein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael H. Greenhawt, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Debra Linzer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mike Cusnir, MD
This Doctor is OpenDoctor Recommended.
|